Results 61 to 70 of about 30,982 (215)

Effectiveness of the first and the second dose of COVID-19 vaccines in Serbia during the first three months of rollout [PDF]

open access: yesSrpski Arhiv za Celokupno Lekarstvo
Introduction/Objective. The main aim of this study was to assess COVID-19 vaccination effectiveness (VE) of BBIBP-CorV, Gam-COVID-Vac, BNT162b2, and ChAdOx1-nCoV-19 in Serbia during the first three months of rollout. Methods.
Đorđević Nataša   +14 more
doaj   +1 more source

SARS-CoV-2 S-RBD IgG & Neutralizing antibodies among different categories of health care workers post third dose BNT162b2 mRNA COVID-19 vaccine

open access: yesHuman Vaccines & Immunotherapeutics, 2023
Neutralizing antibodies (NTAb) play a significant role in preventing and protecting against SARS-CoV-2 virus infection. Identifying NTAb is undoubtedly imperative in understanding the immunity toward COVID-19 better.
Wan Muhammad Azfar Wan Shuaib   +7 more
doaj   +1 more source

Serum levels of prostate specific antigen (PSA) after primary vaccination with BNT162b2

open access: yes, 2023
We retrospectively analyzed 37 male healthy employees (mean age: 61±8 years) of the Pederzoli Hospital in Peschiera del Garda (Verona, Italy) who completed a primary vaccination cycle with the COVID-19 vaccine BNT162b2.
Giuseppe Lippi   +7 more
core   +1 more source

Risk of herpes zoster following mRNA COVID-19 vaccine administration

open access: yesExpert Review of Vaccines, 2023
Background Adverse events following mRNA COVID-19 vaccines, including herpes zoster (HZ), have been reported. We conducted a cohort study to evaluate the association between mRNA COVID-19 vaccination and subsequent HZ at Kaiser Permanente Southern ...
Ana Florea   +7 more
doaj   +1 more source

Immune Responses After Vaccination With Primary 2-Dose ChAdOx1 Plus a Booster of BNT162b2 or Vaccination With Primary 2-Dose BNT162b2 Plus a Booster of BNT162b2 and the Occurrence of Omicron Breakthrough Infection

open access: yesJournal of Korean Medical Science, 2023
Before the omicron era, health care workers were usually vaccinated with either the primary 2-dose ChAdOx1 nCoV-19 (Oxford-AstraZeneca) series plus a booster dose of BNT162b2 (Pfizer-BioNTech) (CCB group) or the primary 2-dose BNT162b2 series plus a booster dose of BNT162b2 (BBB group) in Korea.The two groups were compared using quantification of the ...
Seong-Ho Choi   +6 more
openaire   +2 more sources

Safety of heterologous ChAdOx1-S/BNT162b2 primary schedule versus homologous BNT162b2 vaccination: Insights from an Italian post-marketing study, 2021

open access: yes, 2023
During COVID-19 vaccination campaign, possible ChAdOx1-S-associated risks of thrombosis with thrombocytopenia syndrome led to implement ChAdOx1-S/BNT162b2 heterologous vaccination, despite the limited information on its reactogenicity and safety.
Francesca Fortunato   +13 more
core   +1 more source

BNT162b2 covid-19 vaccine summary of findings table (RCT).

open access: yes, 2023
BNT162b2 covid-19 vaccine summary of findings table (RCT).
Ameer Hohlfeld (6059231)   +10 more
core   +1 more source

BNT162b2 covid-19 vaccine summary of findings table (observational).

open access: yes, 2023
BNT162b2 covid-19 vaccine summary of findings table (observational).
Ameer Hohlfeld (6059231)   +10 more
core   +1 more source

Pfizer SARS-CoV-2 BNT162b2 mRNA vaccination (BNT162b2) has no adverse effect on elective oocyte cryopreservation outcomes

open access: yesReproductive BioMedicine Online, 2022
Do elective oocyte cryopreservation outcomes in women 1-13 months after SARS-CoV-2 vaccination alter compared with unvaccinated women and do different time intervals between vaccination and ovarian stimulation impact these outcomes?This retrospective cohort study, conducted in a university-affiliated IVF centre, included 232 elective oocyte ...
Gilad Karavani   +7 more
openaire   +2 more sources

Humoral immunity against SARS-CoV-2 evoked by heterologous vaccination groups using the CoronaVac (Sinovac) and BNT162b2 (Pfizer/BioNTech) vaccines in Chile

open access: yesFrontiers in Public Health, 2023
IntroductionSevere acute respiratory syndrome virus 2 (SARS-CoV-2) has caused over million deaths worldwide, with more than 61,000 deaths in Chile. The Chilean government has implemented a vaccination program against SARS-CoV-2, with over 17.7 million ...
Diego A. Díaz-Dinamarca   +30 more
doaj   +1 more source

Home - About - Disclaimer - Privacy